Status:
TERMINATED
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Lead Sponsor:
TG Therapeutics, Inc.
Collaborating Sponsors:
James P. Wilmot Cancer Center
Conditions:
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL
Eligibility Criteria
Inclusion
- Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia, or Non-Hodgkin's Lymphoma
- Refractory to or relapsed after at least 1 prior treatment regimen
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion
- Any major surgery, chemotherapy or immunotherapy within the last 21 days
- Known hepatitis B virus, hepatitis C virus or HIV infection
- Known histological transformation from CLL to an aggressive lymphoma (Richter's)
Key Trial Info
Start Date :
March 27 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 16 2022
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT03379051
Start Date
March 27 2018
End Date
June 16 2022
Last Update
August 22 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
TG Therapeutics Investigational Trial Site
Chicago, Illinois, United States, 60611
2
TG Therapeutics Investigational Trial Site
Rochester, New York, United States, 14642
3
TG Therapeutics Investigational Trial Site
Cleveland, Ohio, United States, 44195